AbbVie and Genmab reported Phase 3 success for Epkinly in newly diagnosed diffuse large B-cell lymphoma, cutting the risk of disease progression or death by nearly half versus chemotherapy alone. The results, framed as a first-line win, raise the likelihood of regulatory discussions aimed at earlier use in a high-volume setting. The trial tested Epkinly combined with standard R-CHOP against placebo plus R-CHOP in intermediate- or high-risk patients. The companies said the overall dataset exceeded investor expectations and positioned the regimen to potentially challenge existing standards, including Roche’s Polivy. As bispecific antibodies expand into earlier lines, this result strengthens the competitive bar for safety management and delivery logistics across community and academic centers.